Last reviewed · How we verify
Moderate Alcohol
At a glance
| Generic name | Moderate Alcohol |
|---|---|
| Sponsor | Syracuse University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Chronic obstructive pulmonary disease
- Asthma
- Headache
- Nasopharyngitis
- Viral upper respiratory tract infection
- Nausea
- Cough
- Vomiting
- Dizziness
- Bronchitis
- Hypertension
- Back pain
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Moderate Alcohol Consumption and Heart Function in Patients With a Recent Myocardial Infarction (NA)
- The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity (PHASE4)
- A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (PHASE3)
- Pathophysiological Study of the Sensitive Scalp (NA)
- Primary Connections for Youth and Families (NA)
- Barbershop Talk: Reducing Excessive Alcohol Consumption Among Men (NA)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moderate Alcohol CI brief — competitive landscape report
- Moderate Alcohol updates RSS · CI watch RSS
- Syracuse University portfolio CI